- International Flavors reported first-quarter net sales of $2.84 billion, aligning with expectations of $2.83 billion.
- Health & Biosciences achieved net sales of $540 million, surpassing expectations of $530.4 million, marking a 1.7% increase year-over-year.
- Scent segment net sales were $614 million, a decrease of 4.8% year-over-year but still slightly above the estimate of $610.9 million.
- Pharma Solutions posted net sales of $266 million, significantly exceeding the estimate of $232 million, with a robust 17% year-over-year growth.
- Adjusted earnings per share (EPS), excluding amortization, were $1.20, up from $1.13 year-over-year and above the expected $1.13.
- The company maintains its 2025 full-year sales forecast between $10.6 billion and $10.9 billion.
- Full-year adjusted operating EBITDA is projected at $2 billion to $2.15 billion.
- Comparable currency neutral adjusted operating EBITDA is anticipated to grow 5% to 10% year-over-year.
- CEO Erik Fyrwald highlighted disciplined execution and broad-based business growth as the drivers of solid first-quarter results.
- The CEO also noted that growth and productivity initiatives have led to a significant increase in profitability.
- The stock ratings comprised 15 buys, 4 holds, and 2 sells.
Intl Flavors & Fragrances on Smartkarma
Analyst coverage of International Flavors & Fragrances (IFF) on Smartkarma by Baptista Research is notably positive. In their report titled “Innovation & Expansion in Health & Biosciences Driving Our Bullishness,” Baptista Research highlights IFF’s strong financial results for the fourth quarter and full year 2024. With $11.5 billion in sales and a 6% growth in comparable currency-neutral sales, IFF is showing significant progress. The adjusted operating EBITDA also saw a substantial 16% increase, indicating a positive outlook.
Furthermore, Baptista Research‘s report on “Global Expansion” emphasizes IFF’s impressive performance in the third quarter of 2024. The company achieved a revenue growth surpassing $2.9 billion, a 9% increase on a comparable, currency-neutral basis. This growth was primarily driven by volume improvements in key segments such as Nourish, Health & Biosciences, Scent, and Pharma Solutions. Overall, the analyst sentiment leans bullish, reflecting confidence in IFF’s expansion and innovation strategies.
A look at Intl Flavors & Fragrances Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
International Flavors & Fragrances Inc. is positioned for a promising long-term outlook based on a comprehensive analysis using Smartkarma Smart Scores. With strong scores in Value and Momentum, the company showcases robust potential for growth and profitability. Additionally, its moderate scores in Dividend and Growth indicate a stable and sustainable business model, further reinforcing confidence in its future performance. Although the Resilience score is comparatively lower, the overall outlook for Intl Flavors & Fragrances remains positive across key factors.
International Flavors & Fragrances Inc. specializes in creating and supplying flavors and fragrances for various industries, including food, beverage, personal care, and household products. With a focus on developing unique formulas through blending and mixing diverse ingredients, the company stands out for its innovative approach in the competitive market. Leveraging its solid foundation and impressive Smart Scores, Intl Flavors & Fragrances is poised to maintain a favorable position in the industry and drive value for its stakeholders in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
